NCT01599793View on ClinicalTrials.gov

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2018

Conditions
Bone MetastasesCastrate-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

cabozantinib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

magnetic resonance imaging

Undergo MRI

Trial Locations (1)

60637-1470

University of Chicago, Chicago

Sponsors

Collaborators (1)

Endeavor Health
All Listed Sponsors
collaborator

Endeavor Health

OTHER

lead

University of Chicago

OTHER